Streetbeat News

RHHBF

Roche Holding AG

CEO

Severin Schwan

Industry

Medicinal and Botanical Manufacturing

Open

380.00

Mkt cap

291B

Volume

High

380.00

P/E Ratio

32.56

52-wk high

380.00

Low

367.63

Div yield

N/A

52-wk low

243.42

Genentech's Evrysdi shows promising two-year data for treating Spinal Muscular Atrophy (SMA) in children, with most achieving key mobility milestones. The therapy is non-invasive and approved in over 100 countries.

Portfolio Pulse from Benzinga Newsdesk

October 14, 2024 | 6:52 am

Roche's Genentech has announced that its Phase III CENTERSTONE study of Xofluza shows a significant reduction in the transmission of influenza viruses. This is the first antiviral for respiratory viral illness to demonstrate such a benefit in a global Phase III study, potentially easing the burden on healthcare systems.

Portfolio Pulse from Benzinga Newsdesk

September 19, 2024 | 6:03 am

Roche's Genentech and Halozyme have received FDA approval for Tecentriq Hybreza, the first subcutaneous PD-(L)1 cancer immunotherapy. This new option offers faster treatment times and maintains the safety and efficacy of the intravenous version.

Portfolio Pulse from Benzinga Newsdesk

September 13, 2024 | 7:15 am

Roche is enhancing its digital pathology platform by integrating over 20 AI algorithms from eight new collaborators. This move aims to improve cancer diagnostics and personalized healthcare through AI-driven insights.

Portfolio Pulse from Benzinga Newsdesk

September 09, 2024 | 6:16 am

Roche Holding reported its H1 adjusted EPS of CHF 10.23, up from CHF 10.10 year-over-year, and revenue of CHF 29.85 billion, up from CHF 29.78 billion year-over-year.

Portfolio Pulse from Benzinga Newsdesk

July 25, 2024 | 7:38 am

Roche's Genentech has revealed positive Phase I results for its oral GLP-1 receptor agonist CT-996, showing significant weight loss in patients with obesity. The treatment demonstrated a -7.3% weight loss compared to -1.2% in the placebo group, with a favorable safety and tolerability profile.

Portfolio Pulse from Benzinga Newsdesk

July 17, 2024 | 5:48 am

Roche's Genentech has halted the SKYSCRAPER-06 trial after the combination of tiragolumab, Tecentriq, and chemotherapy showed reduced efficacy compared to the comparator arm. The trial did not meet the primary endpoints of progression-free survival and overall survival.

Portfolio Pulse from Benzinga Newsdesk

July 05, 2024 | 3:01 pm

Roche's Genentech has received FDA approval for Vabysmo Prefilled Syringe (PFS), the first and only syringe prefilled with an FDA-approved bispecific antibody to treat retinal conditions that can cause blindness. This product is designed to simplify administration and will be available for people living with wet AMD, DME, and RVO.

Portfolio Pulse from Benzinga Newsdesk

July 05, 2024 | 3:00 pm

Roche's VENTANA DP 200 Digital System has received FDA approval for diagnostic use, enabling pathologists to diagnose patients using digital images. This approval is a significant step in Roche's commitment to digital pathology solutions.

Portfolio Pulse from Benzinga Newsdesk

June 18, 2024 | 6:03 am

Genentech's Phase III STARGLO study shows that Columvi, in combination with chemotherapy, significantly increases survival rates for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The study met its primary endpoint with a 41% reduction in the risk of death. This treatment could offer a new option for patients ineligible for transplants.

Portfolio Pulse from Benzinga Newsdesk

June 17, 2024 | 7:47 am

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.